- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03567993
mHealth Messaging to Motivate Quitline Use Quitting (M2Q2)
mHealth Messaging to Motivate Quitline Use and Quitting (M2Q2): RCT in Rural Vietnam
The mHealth Messaging to Motivate Quitline Use and Quitting, or "M2Q2" study, is a collaborative research project for a mobile health intervention designed to motivate smoking cessation and encourage access to counseling. The study is for men and women smokers in Vietnam's Red River Delta region who are 18 years of age or older.
The primary hypothesis is that smokers in the M2Q2 intervention will have higher rates of smoking cessation, compared with the comparison group.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific aims of the M2Q2 study are:
Aim 1: In collaboration with the Institute of Population, Health, and Development (PHAD) in Vietnam, adapt a current, effective messaging system to Vietnam. The messaging system will:
- Motivate smokers to quit smoking, using tailored messages adapted to be culturally relevant.
- Encourage smokers to accept counseling services from the Quitline, and take advantage of nicotine replacement therapy (NRT) that will be provided by the Quitline to those willing to quit.
Aim 2: To engage with the Quitline, providing additional training in tobacco cessation counseling for those ready to quit, and motivational interventions for those not yet ready to quit.
Aim 3: To evaluate the impact of the messaging system on: access to the Quitline, use of nicotine replacement therapy, increase in self-efficacy, and six-month biochemically verified smoking cessation.
The study will be conducted in the Red River Delta Region, an agriculturally rich and densely populated area in northern Vietnam. Four communes (Viet Hung, Binh Minh, Tan Viet and Bach Sam) located in four different districts in the Hung Yen province will be included in the M2Q2 study, based on their general representativeness to the rural northern Vietnamese population and because the investigators have developed infrastructure to support technology-assisted behavioral interventions through community health centers (CHCs) in these communes. Each of the selected communes satisfy the following criteria: (1) have a community health center with a medical doctor; (2) are not currently participating in other studies for smoking cessation; and (3) have a minimum geographic separation of 12 kilometers (7 miles) from all other study communes to minimize possible contamination.
Recruitment and retention of study participants will be conducted by both CHC staff and community health workers. The investigators will recruit men and women, and plan for recruiting 15% women. The investigators will plan to recruit smokers regardless of their readiness to quit. Participants will not be compensated, other than being provided a cellphone if they currently do not own one.
The duration of an individual subject's participation in the study is 6 months (baseline survey, texting system, quitline data, and the 6-month follow-up survey). The duration anticipated to enroll all study subjects is 2 years, 2 months. The estimated date for the investigators to complete this study with primary analyses is the middle of year 5.
The main dependent variable is patient tobacco cessation rate (quit rate) at six months. The investigators will biochemically verify smoking status at baseline and at six months. The secondary outcome measure is self-efficacy. The investigators will administer an 12-item questionnaire (SEQ-12) to measure self-efficacy at baseline and at six months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hanoi, Vietnam
- Institute of Population, Health, and Development (PHAD)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years of age.
- Resident of a selected commune.
- Be a current smoker.
- Be able to receive texts and read text (literate).
- Not be cognitively impaired (as assessed by study staff).
- Not have helped develop messages used in the intervention.
- Not be a family member of another participant in the study.
Exclusion Criteria:
- <18 years of age.
- Cognitively impaired (as assessed by study staff).
- Pregnant.
- Prisoner.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Comparison
The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
|
Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback.
Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
|
|
Experimental: Intervention
The intervention is designed to encourage and remind smokers of the availability of the Quitline services.
In addition to the one-way motivational messages, the investigators will use two-way assessments.
Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback.
The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
|
Participants randomized to the intervention arm will receive:
Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Tobacco Cessation Rate (Quit Rate) at 6 Months
Time Frame: At 6 months post-randomization
|
7 day point prevalence cessation per self-report with additional carbon monoxide monitor verification for those who report cessation.
|
At 6 months post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Self-efficacy Scores Using the Self Efficacy Questionnaire (SEQ-12)
Time Frame: From randomization to 6 months post-randomization
|
Study team will administer the Self Efficacy Questionnaire (SEQ-12), an 12-item questionnaire to measure self-reported confidence of current and former smokers in their ability to abstain from smoking in high-risk situations (e.g., when facing internal stimuli (e.g., feeling depressed) and external stimuli (e.g., being with smokers)).
The SEQ-12 consists of 12 items; each item is rated on a 5-point Likert scale (1=not at all sure, 2=not very sure, 3=more or less sure, 4=fairly sure, and 5=absolutely sure).
SEQ-12 scores range from 12 to 60, with higher scores indicating greater self-efficacy.
Individual items are summed to compute the total score.
The outcome will measure the change in SEQ-12 scores from baseline to 6 months post-randomization.
|
From randomization to 6 months post-randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rajani S Sadasivam, PhD, University of Massachusetts, Worcester
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- H00012953
- R01TW010647 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use Cessation
-
University of Mississippi Medical CenterNot yet recruitingTobacco Cessation
-
Duke UniversityCompletedSmokeless Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
Loma Linda UniversityUniversity of California, San Francisco; Riverside University Health System...RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in ChildbirthUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco AbstinenceUnited States
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Food and Health Bureau, Hong Kong; Queen... and other collaboratorsCompletedSmoking Cessation | Tobacco Use CessationHong Kong
-
Centre for Addiction and Mental HealthCompletedSmoking Cessation | Tobacco Use CessationCanada
Clinical Trials on Comparison
-
Brendon Gurd, PhDQueen's UniversityUnknown
-
Harvard School of Public Health (HSPH)Massachusetts General HospitalCompletedOncologyUnited States
-
Windsor Sleep Disorders ClinicNot yet recruitingSnoring | Obstructive Sleep Apnea (OSA)
-
Universidad Nacional de RosarioCompleted
-
Johns Hopkins UniversityMedivators CantelCompletedInfectionUnited States
-
Vantive Health LLCBaxter Healthcare Corporation; Gambro Dialysatoren GmbHCompletedRenal Failure Chronic Requiring HemodialysisAustria
-
University of CalgaryCompletedParent-Child Relations | Disturbances in Initiating and Maintaining SleepCanada
-
University of California, San FranciscoLondon School of Hygiene and Tropical Medicine; National Institute of Mental... and other collaboratorsCompleted
-
European Institute of OncologyCompletedBRCA1 Mutation | BRCA2 Mutation | Psychosocial FactorsItaly
-
CHU de Quebec-Universite LavalCompleted